✦ LIBER ✦

Iodine-125 cytotoxicity: Implications for therapy and estimation of radiation risk

✍ Scribed by William D. Bloomer; S.James Adelstein

Book ID: 119024626
Publisher: Elsevier Science
Year: 1981
Weight: 658 KB
Volume: 8
Category: Article
ISSN: 0047-0740
DOI: 10.1016/0047-0740(81)90071-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recent reassessments of radiation risk e

Recent reassessments of radiation risk estimates: Implications for radiation protection

✍ Roger H. Clarke 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 406 KB

Risk estimates for fast neutrons and imp

Risk estimates for fast neutrons and implications for radiation protection

✍ Albrecht M. Kellerer 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 315 KB

Complications associated with preoperati

Complications associated with preoperative radiation therapy and iodine-125 brachytherapy for localized prostatic carcinoma

✍ Robert C. Flanigan; William F. Gee; John Patterson; Bruce A. Lucas; Oscar A. Men 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 386 KB

Treatment of unresectable carcinoma of p

Treatment of unresectable carcinoma of pancreas by iodine-125 brachytherapy and external radiation therapy

✍ M. H. Shiu; B. S. Hilaris; M. F. Brennan 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 122 KB

Interstitial iodine-125 radiation withou

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

✍ Bhadrasain Vikram 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Interstitial iodine-125 radiation withou

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

✍ Haakon Ragde; John C. Blasko; Peter D. Grimm; Gerald M. Kenny; John E. Sylvester 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: This study was designed to evaluate the efficacy of iodine-125 interstitial radiation in the treatment of prostate carcinoma classified as t1 or t2. ## Methods: One hundred twenty-six consecutive patients with adenocarcinoma of the prostate (t1, 23%; t2, 77%) were treated with iodi